申请人:Daiichi Sankyo Company, Limited
公开号:EP2620434A1
公开(公告)日:2013-07-31
To provide potassium salts of substituted cycloalkene derivatives, which suppress the production of an inflammatory mediator caused by intracellular signal transduction or cell activation induced by endotoxin, and crystals thereof. The present invention provides potassium (2-chloro-4-fluorophenyl)[(2R,3R,8R)-7-(ethoxycarbonyl)-2,3-bis(hydroxymethyl)-1,4-dioxaspiro[4.5]deca-6-en-8-yl]sulfonyl}azanide and potassium (2-bromo-4-fluorophenyl)[(2R,3R,8R)-7-(ethoxycarbonyl)-2,3-bis(hydroxymethyl)-1,4-dioxaspiro[4.5]deca-6-en-8-yl]sulfonyl}azanide, each of which suppresses the production of an inflammatory mediator caused by intracellular signal transduction or cell activation induced by endotoxin, crystals thereof, and a pharmaceutical containing any of the same, and a prophylactic and/or therapeutic agent for sepsis containing any of the same.
提供取代的环烷烃衍生物的钾盐及其晶体,它们能抑制由内毒素诱导的细胞内信号转导或细胞活化引起的炎症介质的产生。本发明提供了钾 (2-氯-4-氟苯基)[(2R,3R,8R)-7-(乙氧基羰基)-2,3-双(羟甲基)-1,4-二氧杂螺[4.5]癸-6-烯-8-基]磺酰基}氮杂烷和(2-溴-4-氟苯基)[(2R,3R,8R)-7-(乙氧羰基)-2,3-双(羟甲基)-1,4-二氧杂螺[4.5]癸-6-烯-8-基]磺酰基}氮杂酰胺,其中每一种都能抑制由内毒素诱导的细胞内信号转导或细胞活化引起的炎症介质的产生,其晶体,以及含有其中任何一种的药物,和含有其中任何一种的败血症预防剂和/或治疗剂。